Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2014

View Archived Issues

Brazilian researchers characterize novel small-molecule inhibitors of inflammatory cytokines

Lanreotide autogel improves symptoms of diarrhea and QoL

Novel topical formulation of alpha-LACE for the treatment of presbyopia

Cortistatin derivative shows potential in experimental CNV

Alcobra to initiate phase IIb study of metadoxine in Fragile X syndrome

Pharmacokinetic data presented for novel cyclic boronic acid beta-lactamase inhibitor

Nuvilex and University of Northern Colorado to research cannabinoids for cancer

U.S. investigators patent novel steroids acting on GABA(A) receptors

AMAGINE-1 study of brodalumab in moderate to severe plaque psoriasis meets endpoints

ReNeuron presents promising phase I data for the CTX0E03 cell therapy in stroke patients

Tripeptide KdPT evaluated in proof-of-concept ulcerative colitis trial

Takeda reviews highlights of fourth quarter of fiscal 2013

AC Immune and Piramal Imaging form agreement for Tau protein diagnostics

Novavax reports follow-up data from phase I RSV F-protein vaccine trial

Abeona Therapeutics' therapies obtain orphan drug designation for Sanfilippo syndrome

Lilly reports positive phase III results for insulin peglispro

Results from phase IIb studies of MedImmune's mavrilimumab and sifalimumab

Idenix Pharmaceuticals reports discovery of dinucleotide compounds for HCV

Janssen Pharmaceutica discloses new ROR-gamma modulators

Novel C9orf72 mRNA expression modulators disclosed by Isis Pharmaceuticals

Tesaro reports positive data from phase III trial of rolapitant

Santhera's phase III study of idebenone for DMD meets primary endpoint

GSK's darapladib misses primary endpoint in acute coronary syndrome trial

Shire acquires Lumena Pharmaceuticals and two new therapeutic compounds

AstraZeneca announces phase III results for saxagliptin/dapagliflozin combination

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...